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Introduction 
An acute coronary syndrome (ACS) without ST-segment 
elevation (NSTEMI)1 or T-wave inversion requires special 
treatment in those patients admitted to the emergency depart-
ment (ED) with strong chest pain. 2,3 A history of previous 
cardiovascular diseases, electrocardiogram (ECG) changes, 
on admission as well as potential risk factors such as sex, age,4 
smoking, hypertension, and diabetes mellitus could provide 
helpful information about the health conditions of patients.  
In making adequate triage diagnostic and early therapeutic  
decisions different biochemical blood biomarkers5-10 as risk  
indicators could be important in predicting the development  
of future possible cardiovascular disorders. 
As a risk-predicting biomarker in patients with ACS, pla-
cental growth factor (PlGF)11 was recently shown to be impor-
tant in early and advanced atherosclerotic lesions and coronary 
plaque rupture. This biomarker could be up-regulated in the 
crucial mechanism of atherosclerosis in ACS patients12  based 
on subsequent platelet aggregation and systematic thrombosis, 
which may lead to the acute myocardial infarction (AMI)  
or sudden cardiac death. Hence, as a member of the vascular  
endothelial growth factor family (VEGF)13 PlGF may be a  
primary inflammatory instigator of atherosclerotic plaque  
instability during the acute phase of ACS.
Accordingly, we attempted to establish the potential prog-
nostic value of PlGF in ACS patients with non ST-segment 
elevation for the recurrence of a new vascular event, including 
death and non-fatal MI after 30 days of follow up. 
Materials and Methods
Subjects
The study protocol No. 01/33 was approved by the Clini-
cal Center of Kragujevac Institutional Ethics Review Comittee, 
and written informed consent was obtained from all participat-
ing patients. We enrolled 102 patients presenting acutely with 
ACS who had chest pain at rest within the preceding 12 hours. 
Variables associated with coronary events were sex, previous his-
tory of coronary artery disease (CAD), diabetes mellitus (DM), 
chronic infections, and smoking. Obesity and body mass index 
(BMI) were the risk factors observed at presentation, and we 
paid attention to shortness of breath as a symptom of current 
physical condition of patients. 
Study patients had peripheral venous blood samples drawn 
at presentation because PlGF is detectable in the peripheral 
circulation. These samples were centrifuged and serum was used 
for analysis at the Institute of Biochemistry. After 30 days, 53 
patients survived, and 49 of them died. There were no patients 
lost due to follow up.
PlGF Biomarker Method
PlGF was determined in 102 patients within the 12 hours 
after pain onset. These patients were followed up for 30 days 
when the second determination of this marker was obtained. 
Quantitative detection of PlGF serum concentrations was per-
formed using an enzyme linked immunosorbent assay (ELISA) 
technique based on a commercially available assay kit (R&D 
Systems, Minneapolis, MN).14 
Statistical Analysis        
Statistical analysis was performed using an SPSS software 
package (SPSS, Chicago, IL). Descriptive statistics were given as 
mean ± SD. The primary end point was mortality or non-fatal 
myocardial infarction during 30 days of follow-up. Risk fac-
tors (sex, previous history, diabetes mellitus, chronic infections, 
smoking, obesity, and BMI) as well as ECG data (ST-segment 
depression, T-wave inversion) were taken as independent vari-
ables. Namely, the effect of baseline characteristics between 
PlGF levels and cardiovascular events was analyzed using a 
stepwise multivariable adjusted for sex, previous history, dia-
betes mellitus, chronic infections, smoking, obesity, BMI, and 
ST-segment changes. Multiple regression analysis was applied in 
order to evaluate the relationship between PlGF and short-term 
outcome and a probability value of P<0.05 was considered sig-
nificant. Box and Whisker plots were used to display analyzed 
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data. Additional analyses were 
performed in the group of pa-
tients who survived the first 30 
days, using Kaplan-Meier, with 
fatal events counted after this 
period. 
Results 
At the beginning of our 
experiment we included 102 
ACS patients admitted to the 
ED. Based on ECG changes 
recorded at the admission we 
separated 66 (64.70%) patients 
with ST-segment depression 
and 36 (35.29%) patients with 
T-wave inversion (Table 1). The 
rationale for separating  ST-segment depression and T-wave 
inversion groups was the difference between the duration of ST-
segment depression (80-120ms) and the appearance of T-wave. 
Putting the patients into these 2 groups was the consequence 
of recorded changes of their ECG. Neither of them had a worse 
outcome than the other. Of 102 patients who were eligible, 
70 (68.62%) were men and 32 (31.4%) were women mean age 
56 (50%). Of them, 56 (54.90%) had a statistically significant 
(P<0.05) history of cardiovascular disease in the ST-group. 
Forty-seven (46.07%) had diabetes mellitus, 68 (66.66%) had 
chronic infections, and 59 (57.84%) reported being current 
smokers. At the time of presentation, 31 (30.39%) of patients 
were obese, and the value of BMI was a total of 62 (60.78%). As 
illustrated in Table 1, the concentrations of PlGF dependents 
mostly with a previous history of cardiovascular disease, obesity, 
and body mass index (P<0.05). The time course of PlGF levels 
based on 102 observed patients (Figure 1) showed mean of 
13.21 ng/L and standard deviation of 8.76 ng/L. After 30 days 
49 (48.00%) patients died (P<0.05) and 53 (51.96%) survived. 
Of the 53 who survived, the PlGF concentration decreased to 
a mean of 10.48 ng/L and a standard deviation of 5.45 ng/L 
(Figure 2). A line graph linking before and after would clearly 
provide the PlGF levels of the 53 surviving patients and illus-
trate how these levels fell in a majority of the cases (Figure 3). 
Kaplan-Meier curves of myocardial infarction of deaths during 
the 30-day follow up were used to compare the survival group 
PlGF levels vs. the non-survival group levels and to illustrate 
prognostic value of the tests.  As shown in Figure 4, dotted line 
= PLGF > 13.21 ng/L. 
All patients received antiplatelet therapy (aspirin or 
clopidogrel), unfractionated heparin, GP IIb/IIIa inhibitors, 
beta blockers, and, if indicated, oral ACE inhibitors. Patients 
received no antiinflammatory drugs, except aspirin.
Placental growth factor was determined in 105 healthy vol-
unteers, and the value of upper reference limit was 25.8 ng/L.
Table 1_The Values of Serum PlGF Concentrations of ACS Patients and Risk Factors 
Observed at Admission
Risk Factors Status of Patients Number of Observed Patients (%) Mean 
ECG ST 66 (64.70%) 12.46 ± 8.85
ECG T 36 (35.29%) 14.56 ± 8.55
Sex Male 70 (68.62%) 13.56 ± 8.21
Sex Female 32 (31.37%) 12.44 ± 9.95
Previous history Yes 56 (54.90%) 13.76 ± 8.46
DM Yes 47 (46.07%) 12.39 ± 8.06
Chronic infection Yes 68 (66.66%) 12.22 ± 8.63
Smoker Yes 59 (57.84%) 13.31 ± 8.54
Obesity Yes 31 (30.39%) 15.37 ± 7.97
BMI Normal 62 (60.78%) 12.80 ± 9.25
Statistic data were given as mean ± SD, and a probability value of p<0.05 was considered significant.
Figure 1_The PlGF levels for 102 observed patients at admission. Figure 2_The comparison between PlGF concentrations at admission 
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Discussion
It is estimated that in all patients, ACS is recognized by the 
ordinary cardiologist because of typical and extremely strong 
chest pains. For such patients the presence of thrombogenic 
contents in the circulation15,16 could be responsible for the 
plaque rupture in these unstable coronary conditions. The most 
cases of ACS17,18 are results of platelet activation and existing 
thrombus formation which could cause possible atherosclerosis. 
It is possible to take a lot of already familiar cardiac markers, 
but we decided to observe the role of PlGF as a member of the 
vascular endothelial growth factor (VEGF) family in patients 
with coronary heart disease. The present findings indicate that 
the concentration of PlGF, a more specific marker of vascular 
inflammation, is significantly changed at the admission in com-
parison to the history of previous cardiovascular disease in 56 
patients, as well as in correlation with the obesity in 31 patients. 
At the same time, 62 patients showed a change of PlGF con-
centration associated with determined value of BMI risk fac-
tor. All these risk factors could potentially change PlGF serum 
concentrations and make it relevant at the admission to the 
ED. Pilarczyk et al19 tested a hypothesis that PlGF-expression 
in human atherosclerotic carotid plaques is related to inflam-
mation, vascularization, and clinical plaque instability mediates 
angiogenesis with inflammation. Namely, this biomarker could 
be released into vulnerable plaques from damaged cardiomyoc-
ites and the degree of injured vascular endothelium apparently 
determines the induction of PlGF very early after the onset of 
MI, which have been reported Iwama et al.20 Since the pathway, 
which is leading to up-regulating of PlGF expression level, is not 
known yet, we could take the possibility that the concentration 
of this biomarker can be regulated by the duration of the acute 
phase of MI. A physiologically active biomarker, PlGF recruits 
macrophages that have important roles in removing necrotic tis-
sue from an injured area and promote the mobilization of bone 
marrow monocytes into the same inflammatory atherosclerotic 
lesions causing the process of pathological angiogenesis. As it is 
already shown in some previous studies21-24  serum PlGF con-
centrations in patients who presented to the ED with chest pain 
are involved in tissue repair of injured myocardium. It is evident 
that the degree of PlGF production released from the heart after 
a heart attack correlated with the improvement of cardiac func-
tion and therefore, PlGF might enhance wound healing and 
become important in the clinical treatment of  MI. 
Our results based on all selected NSTEMI patients suggest 
that altered serum PlGF levels may be a relevant predictor of 
plaque instability in the first few hours after admission to the 
ED. The predictive value of PlGF was independent of hsCRP, 
a biomarker of general inflammation. This means that PlGF 
provides prognostic value independently25,26 of hsCRP and 
could serve as an important clinical factor in the prediction of 
the further development of MI providing useful information in 
determining future ACS risk.
Interestingly, baseline PlGF was also associated with an in-
creased risk of cardiovascular complications during the 30 days 
of follow-up in survived patients. These data add to the growing 
evidence showing that hsCRP as a classic systemic acute-phase 
protein might not be specific enough for the inflammation 
process involved in vascular atherosclerosis.27 Therefore, hsCRP 
levels collected in ACS patients seem to be less useful as a tool 
for cardiovascular risk stratification and patient management. 
In contrast, PlGF as a more specific marker of vascular inflam-
mation, providing independent predictive value for the short-
term cardiovascular outcome is not hampered by the occurrence 
of an ACS28 and therefore playing a very important role in 
clinical decision making. 
Our results confirmed that the plaque instability, rep-
resented by PlGF elevation upon admission, could have an 
important role in the pathogenesis of future coronary events in 
patients with NSTEMI. Future studies of the role of new car-
diac markers implied in clinical practice should assess a poten-
tial long-term benefit of this biomarker in ACS patients. 
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